stockrow
Friday 6 November 2026
Export ATRC’s income statement to Excel — free account
AtriCure, Inc.
ATRC Healthcare Medical Instruments & Supplies
AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024.
- Revenue
- +15.0%
- EPS
- +1,583.9%
- Free cash flow
- −0.73%
- Total debt
- −17.3%
Quarter to September 2026, against a year earlier
59.84
1.44
−2.35%
Follow ATRC
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 129.18 | 184.08 |
P/S ratio |
3.53 | 2.50 | 2.39 | 4.66 | |
P/FCF ratio |
103.31 | 58.32 | 58.91 | 119.80 | |
P/Operating CF |
94.32 | (345.09) | 61.36 | 123.82 | |
P/B ratio |
3.84 | 2.80 | 2.64 | 5.15 | |
Price to Tangible BV |
9.03 | 6.53 | 5.71 | 10.67 | |
EV/Sales |
3.40 | 2.40 | 2.26 | 4.48 | |
EV/EBITDA |
157.03 | 72.75 | 37.60 | 77.28 | |
EV/Operating CF |
31.67 | 20.59 | 19.80 | 38.55 | |
EV/FCF |
99.30 | 56.05 | 55.62 | 115.21 | |
Quick Ratio |
2.87 | 2.97 | 3.02 | 3.13 | |
Current Ratio |
3.96 | 4.29 | 4.22 | 4.33 | |
Net Debt/EBITDA |
(12.19) | (12.60) | (6.42) | 0.00 | |
Debt/Assets |
11.22% | 11.15% | 10.50% | 8.50% | |
Debt/Equity |
0.15 | 0.15 | 0.14 | 0.11 | |
Asset Turnover |
0.85 | 0.89 | 0.89 | 0.87 | |
Operating CF/Net income |
11.40 | (37.00) | 2.48 | 0.00 | |
Capex/Depreciation |
(0.31) | (0.72) | (0.70) | 0.00 | |
Interest Coverage |
1.66 | 0.39 | 7.33 | 2.70 | |
Research and Development Expense of Revenue |
17.44% | 17.16% | 17.19% | 20.79% | |
Selling, General and Administrative Expense of Revenue |
55.76% | 59.86% | 53.75% | 53.66% | |
Intangible Assets out of Total Assets |
0.43 | 0.44 | 0.41 | 0.38 | |
Share Based Compensation of Revenue |
8.01% | 7.98% | 8.02% | 0.00% | |
Graham Net Nets |
0.08 | 0.12 | 0.14 | 0.07 | |
Graham Number |
0.00 | 0.00 | 7.19 | 8.66 | |
Earnings Yield |
(0.60%) | (0.33%) | 0.77% | 0.54% | |
Free Cash Flow Yield |
0.97% | 1.71% | 1.70% | 0.83% | |
Revenue per Share |
2.94 | 2.92 | 3.16 | 3.16 | |
Operating CF per Share |
0.42 | (0.08) | 0.46 | 0.00 | |
Capex per Share |
(0.03) | (0.08) | (0.08) | 0.00 | |
Free Cash Flow per Share |
0.39 | (0.16) | 0.38 | 0.00 | |
Cash per Share |
3.51 | 3.02 | 3.45 | 3.83 | |
Shareholders Equity per Share |
10.30 | 10.17 | 10.61 | 10.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.30 | 10.17 | 10.61 | 10.91 | |
Free Cash Flow |
18.43 | (7.85) | 18.43 | 23.93 | |
Working Capital |
241.00 | 240.50 | 263.62 | 279.42 | |
Capital Expenditures |
(1.60) | (3.85) | (3.77) | (6.39) | |
Net Current Asset Value |
160.27 | 161.40 | 185.32 | 179.08 | |
EV/EBIT |
0.00 | 0.00 | 99.74 | 155.12 | |
Capex to Sales |
0.01 | 0.03 | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 105.64 | 161.30 | |
| Other line items | |||||
Average Receivables |
63.50 | 67.32 | 72.99 | 69.55 | |
Average Payables |
25.17 | 27.87 | 30.76 | 52.86 | |
Average Inventory |
76.91 | 78.03 | 80.13 | 83.13 | |
Average Assets |
631.75 | 617.81 | 642.75 | 676.49 | |
Average Common Equity |
476.45 | 473.16 | 490.46 | 504.87 |
Columns are period end dates · fundamentals updated 5 Nov 2026